Navigation Links
China Bio-Immunity Corporation - Rabies Vaccine Recall

DALIAN, China, March 5 /PRNewswire-FirstCall/ -- China Bio-Immunity Corporation (OTC Bulletin Board: CHHB) (China Bio-Immunity" or "the Company"), a China-based company that develops, produces, manufactures and markets proprietary vaccine-based prophylactics and therapeutics exclusively within China through it wholly-owned subsidiary, Dalian Jingang-Andi Bio-products Co. Ltd (Dalian JGAD), today announced an update regarding the nationwide recall of its rabies vaccines.

The National Institute for the Control of Pharmaceutical and Biological Products has reported that the Company's flawed rabies vaccines contained nucleic acid, which as a prescription drug has been legally produced by more than twenty manufacturers in China and widely used in the Chinese market. However, it has not yet been approved as an ingredient to be added in human rabies vaccine in China. Although tests on animals demonstrated that the nucleic acid did enhance the effectiveness of the human rabies vaccine, it had to undergo clinical trials before it could be used as an adjuvant in human rabies vaccines. Dalian JGAD was found falling afoul of such regulatory rules. Among 360,200 doses of the flawed rabies vaccines in China, a total of 323,200 have been recovered by the manufacturer, Dalian JGAD. The rest of the rabies vaccines were not used and had been held for recall. To date, there has been no report of vaccine related illness received by Chinese National Center for Adverse Drug Reaction Monitoring.

Furthermore, the China State Food and Drug Administration ("SFDA") has confiscated all the flawed products and profits from the sales of the flawed rabies vaccines. The SFDA will also assess a punitive fine of 145 Million Chinese Yuan. Dalian JGAD has been suspended from production and sales of vaccines since the recall. The production permit of Dalian JGAD was also revoked. Additionally, the key officers involved have been forbidden from engaging in any production activities within the pharmaceutical industry for a period of ten years. Two senior executives and one purchasing agent of Dalian JGAD have been detained by local authorities.

Safe Harbor Statement

The Statements contained in this press release are being made on the basis of the Company's review of the situation to date. Furthermore, the information contained herein may change as the governmental investigation is ongoing. Additionally, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward looking statements in this press release.

SOURCE China Bio-Immunity Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer ... that they have entered into a multiyear collaboration to identify and characterize novel ... additional tools for gene editing across all applications. , Under the terms of ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract research, ... improve patient outcomes and quality of life, will now be offering its impurity ... to new regulatory requirements for all new drug products, including the finalization of ...
(Date:10/11/2017)... CA (PRWEB) , ... October 11, 2017 , ... ... upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding the ... system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... Md. (PRWEB) , ... October 11, 2017 , ... ... digital pathology, announced today it will be hosting a Webinar titled, “Pathology is ... Advanced Pathology Associates , on digital pathology adoption best practices and how Proscia ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
Breaking Biology News(10 mins):